Stockreport

Tiziana Life Sciences to Dose First Patient in Phase 2 Alzheimer’s Trial

Tiziana Life Sciences Ltd - Common Shares  (TLSA) 
PDF First Patient Expected to be Dosed Next Week with Intranasal ForalumabPET Scan Shows Presence of Untreated Neuroinflammation in Alzheimer’s Patient on Leqembi® (Lecanema [Read more]